Delcath to present phase 2 trial results at ESMO congress

NEW YORK - Delcath Systems, Inc. (NASDAQ:DCTH), a healthcare company with an impressive 85.86% gross profit margin and strong revenue growth of 491% over the last twelve months according to InvestingPro, announced that results from the CHOPIN randomized Phase 2 trial will be presented at the European Society for Medical Oncology (ESMO) Annual Congress on October 18, 2025.

The presentation will feature data evaluating the company’s CHEMOSAT Hepatic Delivery System for percutaneous hepatic perfusion with melphalan, used in combination with immunotherapy drugs ipilimumab and nivolumab in patients with metastatic uveal melanoma. InvestingPro data shows the company maintains a healthy financial position with more cash than debt on its balance sheet and a strong current ratio of 10.88x.

Dr. Ellen Kapiteijn from Leiden University Medical Center’s Department of Medical Oncology will deliver the oral presentation titled "Combined Percutaneous Hepatic Perfusion with Ipilimumab plus Nivolumab in Metastatic Uveal Melanoma: a single center, open-label, randomized, phase 2 study."

Delcath Systems specializes in interventional oncology treatments for primary and metastatic liver cancers. The company’s HEPZATO KIT received FDA approval in the United States as a liver-directed treatment for adult patients with metastatic uveal melanoma with specific disease characteristics.

In Europe, the company markets a device-only configuration under the name CHEMOSAT Hepatic Delivery System for Melphalan, which has been used to treat various liver cancers.

The CHOPIN trial results will be presented during the "Melanoma and other skin tumours" session at the ESMO congress. According to the company’s press release statement, the poster will be available on Delcath’s website when the ESMO embargo lifts on October 18. With the stock currently trading near $11.56 and analysts setting price targets between $21 and $31, investors can access detailed valuation analysis and 12 additional ProTips through InvestingPro’s comprehensive research reports.

In other recent news, Delcath Systems Inc. reported impressive financial results for the second quarter of 2025. The company posted earnings per share of $0.07, significantly exceeding analyst projections of $0.03. Revenue also outperformed expectations, coming in at $24.2 million versus the anticipated $22.78 million. Additionally, Delcath Systems announced the commencement of a global Phase 2 clinical trial for its HEPZATO treatment in combination with other drugs for liver-dominant metastatic colorectal cancer. The trial, which has begun dosing patients at City of Hope National Medical Center, will involve approximately 90 participants across more than 20 sites in the United States and Europe. These developments highlight Delcath’s ongoing efforts in advancing its treatment options and achieving strong financial performance.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.